Vaccine Design pp 397-408 | Cite as

The Design of a Clostridium difficile Carbohydrate-Based Vaccine

  • Mario A. MonteiroEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1403)


Clostridium difficile vaccines composed of surface polysaccharides (PSs) have the potential to simultaneously control infection and colonization levels in humans. Hot water–phenol treatment of C. difficile biomass can extricate water-soluble PS-I and PS-II; and water- and phenol-soluble PS-III. C. difficile vaccines based on PS-II have attracted the most attention due its facile purification and ubiquitous expression by C. difficile ribotypes. Anti PS-II antibodies recognize both C. difficile vegetative cell and sporulating preparations and confer protection against C. difficile infection in a mouse model. The design of such an efficacious C. difficile PS-II conjugate vaccine is described here.

Key words

Clostridium difficile Vaccine Polysaccharide C. difficile PS-II Conjugate TEMPO-mediated conjugation 



This work was supported in part by a Discovery grant from the Natural Sciences and Engineering Research Council (Canada) to M.A.M. The KLH conjugation immunogenic analysis and mouse model studies were funded and carried out by Stellar Biotechnologies, Inc. (Herbert Chow, Martin Sagermann).


  1. 1.
    Ganeshapillai J, Vinogradov E, Rousseau J, Weese JS, Monteiro MA (2008) Clostridium difficile cell-surface polysaccharides composed of pentaglycosyl and hexaglycosyl phosphate repeating units. Carbohydr Res 343:703–710CrossRefPubMedGoogle Scholar
  2. 2.
    Monteiro MA, Ganeshapillai J (2013) Polysaccharide immunogens from Clostridium difficile. US Patent 8597663 B2, 3 Dec 2013Google Scholar
  3. 3.
    Danieli E et al (2011) First synthesis of C. difficile PS-II cell wall polysaccharide repeating unit. Org Lett 13:378–381CrossRefPubMedGoogle Scholar
  4. 4.
    Oberli MA et al (2011) A possible oligosaccharide-conjugate vaccine candidate for Clostridium difficile is antigenic and immunogenic. Chem Biol 18:580–588CrossRefPubMedGoogle Scholar
  5. 5.
    Adamo R et al (2012) Phosphorylation of the synthetic hexasaccharide repeating unit is essential for the induction of antibodies to Clostridium difficile PSII cell wall polysaccharide. ACS Chem Biol 7:1420–1428CrossRefPubMedGoogle Scholar
  6. 6.
    Martin CE, Weishaupt MW, Seeberger PH (2011) Progress toward developing a carbohydrate-conjugate vaccine against Clostridium difficile ribotype 027: synthesis of the cell-surface polysaccharide PS-I repeating unit. Chem Commun (Camb) 47:10260–10262CrossRefGoogle Scholar
  7. 7.
    Jiao Y et al (2013) Clostridium difficile PSI polysaccharide: synthesis of pentasaccharide repeating block, conjugation to exotoxin B subunit, and detection of natural anti-PSI IgG antibodies in horse serum. Carbohydr Res 378:15–25CrossRefPubMedGoogle Scholar
  8. 8.
    Reid CW et al (2012) Structural characterization of surface glycans from Clostridium difficile. Carbohydr Res 354:65–73CrossRefPubMedGoogle Scholar
  9. 9.
    Martin CE et al (2013) Glycan arrays containing synthetic Clostridium difficile lipoteichoic acid oligomers as tools toward a carbohydrate vaccine. Chem Commun (Camb) 49:7159–7161CrossRefGoogle Scholar
  10. 10.
    Wouter FJ et al (2014) Total synthesis of five lipoteichoic acids of Clostridium difficile. Chemistry 20:13511–13516CrossRefGoogle Scholar
  11. 11.
    Bertolo L et al (2012) Clostridium difficile carbohydrates: glucan in spores, PSII common antigen in cells, immunogenicity of PSII in swine and synthesis of a dual C. difficile-ETEC conjugate vaccine. Carbohydr Res 354:79–86CrossRefPubMedGoogle Scholar
  12. 12.
    Hobson PN, Nasr H (1951) An amylopectin-type polysaccharide synthesised from sucrose by Cl. butyricum. J Chem Soc 1855–1857Google Scholar
  13. 13.
    Whyte JNC, Strasdine GA (1972) An intracellular alpha-D-glucan from Clostridium botulinum, type E. Carbohydr Res 25:435–441CrossRefPubMedGoogle Scholar
  14. 14.
    Monteiro MA et al (2013) Carbohydrate-based Clostridium difficile vaccines. Expert Rev Vaccines 12:421–431CrossRefPubMedGoogle Scholar
  15. 15.
    Chow H, Sagermann M, Ma Z, Vandentam G, Monteiro MA (2013) Vaccination with Clostridium difficile PSII polysaccharide antigen adjuvanted with KLH induced broad-based enhancement of adaptive immune responses and protection in mice. Paper presented at the 7th Vaccine and ISV Congress Sitges, Spain, 27–29 Oct 2013; and Pequegnat B, Sagermann M, Arroyo L, Chow H, Monteiro MA (2013) An anti-C. difficile PSII polysaccharide-KLH conjugate vaccine is efficacious in mice. Paper presented at the international conference on the molecular biology and pathogenesis of the Clostridia (ClostPath 8), Queensland, Australia, 22–26 Oct 2013Google Scholar
  16. 16.
    Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685CrossRefPubMedGoogle Scholar
  17. 17.
    Towbin H, Staehelin T, Gordon J (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 76:4350–4354CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Chen X, Katchar K, Goldsmith JD et al (2008) A mouse model of Clostridium difficile-associated disease. Gastroenterology 135:1984–1992CrossRefPubMedGoogle Scholar
  19. 19.
    Ma Z, Bertolo L, Arar A, Monteiro MA (2011) TEMPO-mediated glycoconjugation: a scheme for the controlled synthesis of polysaccharide conjugates. Carbohydr Res 346:343–347CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.University of GuelphGuelphCanada

Personalised recommendations